- Covers the evolving regulatory landscape, as well as current and future use of digital technologies.
- Uses case studies to ensure content is relevant to everyday practice.
- Discusses behavioral science and patient perspectives, risk communication, and new frontiers in pharmacovigilance.
- Consolidates today's available information on this timely topic into one convenient resource.
Written by experts in the field of pharmacovigilance and patient safety, this concise resource provides a succinct, easy-to-digest overview of an increasingly critical area of medical safety. Drs. Thao Doan, Cheryl Renz, Fabio Lievano, Mondira Bhattacharya, and Linda Scarazzini provide essential information for health care professionals, clinical researchers, and regulators who need a comprehensive, up-to-date source of information on the principles and practice of pharmacovigilance.
Key Features
- Covers the evolving regulatory landscape, as well as current and future use of digital technologies.
- Uses case studies to ensure content is relevant to everyday practice.
- Discusses behavioral science and patient perspectives, risk communication, and new frontiers in pharmacovigilance.
- Consolidates today's available information on this timely topic into one convenient resource.
| ISBN | 9780323581165 |
|---|---|
| Product Format | Book |
| Publication Date | 2018 |
| Author Information | Edited by Thao Doan, MD, Sr. Medical Director, Medical Safety Evaluation, AbbVie Inc., Chicago. IL; Linda Scarazzini, MD , Vice President, Pharmacovigilance and Patient Safety, AbbVie Inc., Chicago. IL; Cheryl Renz, Senior Medical Director, Safety Science, Pharmacovigilance and Patient Safety, AbbVie, North Chicago, Illinois, United States; Fabio Lievano, MD, Vice President, Safety Sciences, Medical Safety Evaluation Pharmacovigilance and Patient Safety AbbVie Inc., Chicago. IL and Mondira Bhattacharya, MD, Head, Benefit-Risk Management, Innovative Platforms Initiative & Epidemiology, Pharmacovigilance and Patient Safety, AbbVie Inc., Chicago. IL |
| Table of Content | Introduction Section I. The Regulatory Enviroment 1. Does Regulation Drive Science or Does Science Drive Regulation? Section II. Data and Real World Evidence 2. Role of Epidemiology in Pharmaceutical Industry 3. Real World Epidemiologic Studies and Patient Registries Section III. Benefit-Risk in the Drug Development Life Cycle 4. Signal Management and Methods of Signal Detection 5. Causality Assessment and Examples of Adverse Drug Reactions (Drug Induced Liver Injury, Skin, Major Adverse Cardiac Events and Renal) 6. Product Safety Monitoring in Clinical Trials 7. Benefit-Risk Assessments 8. Communicating benefit risk 9. Pharmacovigilance and Medical Devices 10. Vaccine Safety Surveillance 11. Pharmacovigilance in Special Populations (Pediatrics and Elderly) 12. Pharmacovigilance in Pregnancy Section IV. The Role of the Digital Revolution 13. Impact and Implications of Technology on Pharmacovigilance Section V. The Next Frontier 14. The Future of Pharmacovigilance |
| Publication Date | 15-08-2018 |
| Pages | 214 |
| Trim | 235 x 191 (7 1/2 x 9 1/4) |
| Stock Status | In Stock |
| deltacomm1code | Books |
